{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:00:52Z","timestamp":1648756852801},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.biologicals.2011.05.001","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T13:03:21Z","timestamp":1309007001000},"page":"236-241","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility of the use of ELISA in an immunogenicity-based potency test of anthrax vaccines"],"prefix":"10.1016","volume":"39","author":[{"given":"Alicia","family":"Jim\u00e9nez-Alberto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Parreiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Castel\u00e1n-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lev","family":"Sirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Arciniega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2011.05.001_bib1","first-page":"1","article-title":"Summary of notifiable diseases \u2013 United States 1998","volume":"47","author":"Groseclose","year":"1999","journal-title":"MMWR"},{"key":"10.1016\/j.biologicals.2011.05.001_bib2","first-page":"1","article-title":"Summary of notifiable diseases \u2013 United States 2006","volume":"55","author":"McNabb","year":"2008","journal-title":"MMWR"},{"key":"10.1016\/j.biologicals.2011.05.001_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nature02763","article-title":"Crystal structure of a complex between anthrax toxin and its host cell receptor","volume":"430","author":"Santelli","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.biologicals.2011.05.001_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1462-5822.2006.00845.x","article-title":"Characterization of the interaction between anthrax toxin and its cellular receptors","volume":"9","author":"Liu","year":"2007","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.biologicals.2011.05.001_bib5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","article-title":"Proteolytic inactivation of MAP\u2013kinase\u2013kinase by anthrax lethal factor","volume":"280","author":"Duesbery","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.biologicals.2011.05.001_bib6","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1073\/pnas.79.10.3162","article-title":"Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells","volume":"79","author":"Leppla","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biologicals.2011.05.001_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: receptor binding, internalization, pore formation, and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.biologicals.2011.05.001_bib8","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/j.vaccine.2006.12.043","article-title":"Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine","volume":"25","author":"Little","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2011.05.001_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.3.3.4011","article-title":"Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge","volume":"3","author":"Huang","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.biologicals.2011.05.001_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.biologicals.2011.05.001_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14787210.7.2.219","article-title":"Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis","volume":"7","author":"Tournier","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.biologicals.2011.05.001_bib12","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1016\/j.vaccine.2008.04.064","article-title":"Working group meeting on standardization of acellular pertussis vaccines: potency assay: Beijing, China, 7\u20139 November 2007","volume":"26","author":"WHO","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2011.05.001_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.8.3.313","article-title":"Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement","volume":"8","author":"Hendriksen","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.biologicals.2011.05.001_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/biol.1998.0154","article-title":"WHO guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines","volume":"26","author":"Arciniega","year":"1998","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2011.05.001_bib15","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2003.12.027","article-title":"Development of an in\u00a0vitro-based potency assay for anthrax vaccine","volume":"22","author":"Little","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2011.05.001_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biologicals.2004.03.002","article-title":"Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice","volume":"32","author":"Pombo","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2011.05.001_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2011.05.001_bib18","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/CVI.00003-08","article-title":"Participating laboratories, interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species","volume":"15","author":"Omland","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.biologicals.2011.05.001_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in\u00a0vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.biologicals.2011.05.001_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/prot.21432","article-title":"Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity","volume":"68","author":"Powell","year":"2007","journal-title":"Proteins"},{"key":"10.1016\/j.biologicals.2011.05.001_bib21","doi-asserted-by":"crossref","first-page":"39897","DOI":"10.1074\/jbc.M508569200","article-title":"Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen","volume":"280","author":"Zomber","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.biologicals.2011.05.001_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0168-1656(96)01569-6","article-title":"Thermostabilization of protective antigen \u2013 the binding component of anthrax lethal toxin","volume":"50","author":"Radha","year":"1996","journal-title":"J\u00a0Biotechnol"},{"key":"10.1016\/j.biologicals.2011.05.001_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bbrc.2004.08.020","article-title":"Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes","volume":"322","author":"Singh","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biologicals.2011.05.001_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2007.04.030","article-title":"Unfolding transitions of Bacillus anthracis protective antigen","volume":"465","author":"Chalton","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.biologicals.2011.05.001_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jps.20484","article-title":"Anthrax vaccine powder formulations for nasal mucosal delivery","volume":"95","author":"Jiang","year":"2006","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.biologicals.2011.05.001_bib26","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.biologicals.2011.05.001_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/CVI.00267-10","article-title":"Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay","volume":"18","author":"Castel\u00e1n-Vega","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.biologicals.2011.05.001_bib28","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2004.10.014","article-title":"Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants","volume":"23","author":"Berthold","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2011.05.001_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-1759(95)00067-K","article-title":"Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model","volume":"183","author":"Reizenstein","year":"1995","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.biologicals.2011.05.001_bib30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biologicals.2008.03.001","article-title":"Evaluation of quantitative anti-F1 IgG and anti-V IgG ELISAs for use as an in\u00a0vitro-based potency assay of plague vaccine in mice","volume":"36","author":"Little","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2011.05.001_bib31","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1016\/j.vaccine.2009.05.045","article-title":"Comparability of ELISA and toxin neutralization to measure immunogenicity of protective antigen in mice as part of a potency test for anthrax vaccines","volume":"27","author":"Parreiras","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2011.05.001_bib32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pds.936","article-title":"Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"13","author":"Sever","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.biologicals.2011.05.001_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/JB.85.1.230-236.1963","article-title":"Studies on immunity in anthrax X gel-adsorbed protective antigen for immunization of man","volume":"85","author":"Puziss","year":"1963","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.biologicals.2011.05.001_bib34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/labinvest.3700041","article-title":"Modeling formalin fixation and antigen retrieval with bovine pancreatic RNase A II. Interrelationship of cross-linking, immunoreactivity, and heat treatment","volume":"84","author":"Rait","year":"2004","journal-title":"Lab Invest"},{"key":"10.1016\/j.biologicals.2011.05.001_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/39.2.1987266","article-title":"Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation","volume":"39","author":"Mason","year":"1991","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.biologicals.2011.05.001_bib36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2011.05.001_bib37","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2011.05.001_bib38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/IAI.70.2.544-550.2002","article-title":"Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization","volume":"70","author":"Kobiler","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.biologicals.2011.05.001_bib39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.vaccine.2007.11.047","article-title":"Improving the cellular pertussis vaccine: increased potency and consistency","volume":"26","author":"Thalen","year":"2008","journal-title":"Vaccine"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105611000625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105611000625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T18:34:54Z","timestamp":1592678094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105611000625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1045105611000625"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2011.05.001","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}